This systematic review synthesizes real-world evidence on the durability of risankizumab treatment in biologic-experienced patients with plaque psoriasis, evaluating treatment persistence and discontinuation patterns in a population that often demonstrates reduced responses to subsequent biologic therapies.
Click-Here-(Apply Form).comCall for Co-AuthorsWe are pleased to announce an open call for:
8 Co-authorship slots on our upcoming cross sectional.
• Prior research or publication experience is not required, we welcome new authors.
• Open to medical students (undergraduate and postgraduate), residents, and MDs.
• This is an excellent opportunity to gain authorship experience and contribute to a published work.
Deadline: January 15, 2026, at 11:59 PMFill out the form at the link above.
Slots are limited please apply promptly.